ãðŽéèŠ/æ°žä¹ ä¿åçãCOVIDïŒã³ãããŠã€ã«ã¹ïŒã¯ã¯ãã³4çš®ã«å«ãŸããã°ã©ãã§ã³ãã¢ã«ãããŠã ãã»ã¬ã³åã«ãããŠã ãã¹ãã³ã¬ã¹éŒãLNP-GOãã£ãã·ããå¯çè«ããã®ä»ã®æ¯çŽ ã®ååšãç§åŠè ããŒã ã確èªããã¡ã€ã¶ãŒç€Ÿãã¢ãã瀟ãã¢ã¹ãã©ãŒãã«ç€Ÿããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ç€Ÿ
ðãã¯ã¯ãã³ã«äœãå
¥ã£ãŠãã®ïŒããšèãããããæ¬èšäºã玹ä»ããŠãã ãããã©ãã ãå±éºããç解ã§ããŸãã
https://note.com/drgngod/n/n6c4170c40092
ââââââââââââââââââââ
ã¹ãã€ã³ãšã¢ã«ãŒã³ãã³ã®å»åŠç 究è
ãé»åé¡åŸ®é¡ãšåå
æ³ãçšããŠçºèŠããããšãèŠäºã«è£ä»ããŠããã®ããã©ã»ãã³ã¿ã»ã³ã«ã ãèªãå ±ãããDr.ãããŒãã»ã€ã³ã°å士ã¯ãçååŠè
ã埮çç©åŠè
ãèšåºæ é€å£«ã§ããããpHãã©ã¯ã«ãã·ãªãŒãºãããªããŒã¹ã»ãã£ã³ãµãŒã»ããŠãã·ãªãŒãºãªã©ã®èæžãããã40幎ã«ãããèšåºã»å»ç埮çç©åŠã®ç 究ãåŠè¡ãæè²ã«æºãã£ãŠããŸããã
圌ãšç 究è
ããŒã ã¯ãééåã»èµ°æ»åé»åé¡åŸ®é¡ãäœçžå·®é¡åŸ®é¡ãXç·åå
æ³ãçšããŠã4çš®é¡ã®ã¯ã¯ãã³ãã¹ãŠã«å«ãŸããé
žåã°ã©ãã§ã³ãšããæ¯çŽ ãç¹å®ãããšå ±åããŠããŸãããã¡ã€ã¶ãŒç€Ÿãã¢ãã瀟ãã¢ã¹ãã©ãŒãã«ç€Ÿããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ç€Ÿã®4瀟ã®ã¯ã¯ãã³ã«å«ãŸããé
žåã°ã©ãã§ã³ãšããæ¯çŽ ãã¯ãããã¢ã«ãããŠã ãã¹ãã³ã¬ã¹ããã¹ãã¹ãé
žåã°ã©ãã§ã³ãã¡ãã°ããè質ããç²åãã£ãã·ãããããŠå¯çè«ã®ã¯ã«ãŒãºããªãããœãŒããªã©ãããŸããŸãªçš®é¡ã®ã¯ã¯ãã³ã«å«ãŸãããã®ã確èªããŸããã
Dr.ã€ã³ã°å士ã¯ããããã®ç 究çµæãèªèº«ã®ãµã€ãã§å ±åããŠããã8æ25æ¥ïŒæ°ŽïŒã®ãã¥ãŒã¹ãã¬ã€ã¯133ã§æ¬èªèšè
ãšè©³çŽ°ã«è°è«ããäžæ°éçãšã¯äœããäœã®äžã§äœãããç
æ°ã®ç¶æ
ãšã¯äœãã詳ãã説æãããŠã€ã«ã¹çè«ã¯ãŸã çè«ã«éãããç§åŠçã«èšŒæããããã®ã§ã¯ãªãããšã説æããŸãããSARS-COV-2ãšæããããŠã€ã«ã¹ã¯äžçã®ã©ãã«ãåé¢ãããŠããããCOVID-19ãšåŒã°ããŠãããã®ã¯ãããæ£ç¢ºã«ã¯ãéå»ã®ã¯ã¯ãã³ïŒãããã¯ãšã¢ããŸã«æ£åžãªã©ã®ä»ã®åå ïŒã«ããé
žåã°ã©ãã§ã³äžæ¯ãš4G/5Gã®æŸå°ç·ç
§å°ãããã§ã«åŒ±ã£ãŠããããç
æ°ã«ãªã£ãŠãã人äœã«äœçšãããååŠç©è³ªãšæŸå°ç·ã®æ¯ãã«èµ·å ããçç¶ã®éãŸãã«ãããªããšããã
ããã¯ãã€ã³ã°å士ã®ã¬ããŒãã§ãã
èµ°æ»åããã³ééåé»åé¡åŸ®é¡ã§CoV-19ã¯ã¯ãã³ã«é žåã°ã©ãã§ã³ãçºèŠ/Robert Youngå士/20幎8æ20æ¥
ãã®å ±åæžã¯ããã®Medic Debateã®ãŠã§ããµã€ãã«ãæ²èŒãããŠãããç§åŠè ããŒã ã®ã¯ã¬ãžãããèšèŒãããŠããŸããã³ãããã»ã¯ã¯ãã³ã®ãããã¯ãããžãŒç 究
COVIDã¯ã¯ãã³4çš®ãSEMãTEMãäœçžå·®ãXç·ã¹ãã¯ããã¹ã³ããŒã§æ€æ»ããã€ã³ãã©ãŒã ãã³ã³ã»ã³ããåŸãçç±ã«ã€ããŠ
Youngå士ã®èšäºã«ããããã«ã€ã³ã°å士ã®è«æã«ããããã«ããã¡ã€ã¶ãŒã»ãã€ãªã³ããã¯ãã¢ããããªãã¯ã¹ãã©ãŒãã»ã¢ã¹ãã©ãŒãã«ãã€ã³ã»ã³ã»ãžã§ã³ãœã³ã»ã¢ã³ãã»ãžã§ã³ãœã³ã®4ã€ã®ã¯ã¯ãã³ã®æ°Žæ§ç»åããç§åŠè
ããŒã ãèµ°æ»åã»ééåé»åé¡åŸ®é¡ïŒSEMã»TEMïŒãäœçžå·®å
åŠé¡åŸ®é¡ããšãã«ã®ãŒåæ£åXç·åå
æ³ãªã©ãçšããŠèª¿ã¹ãŸããããããã®ã¯ã¯ãã³ã¯ãã¯ã¯ãã³ã»ã³ã¿ãŒã«äžŠã¶äººã
ã«ããæäžããå»çåŸäºè
ã«ãããæå³çã«ç©ºçœããšæžããããã€ã¢ã«ã®æ¿å
¥ç©ã䜿ã£ãŠãå®å
šãªæ
å ±é瀺ãããŠããªãããšãããã¯ã¯ãã³ã«å«ãŸããååŠçµæãå
çŽ ã調ã¹ãããã«ãèµ°æ»åããã³ééåé»åé¡åŸ®é¡ïŒSEMããã³TEMïŒãäœçžå·®å
åŠé¡åŸ®é¡ããšãã«ã®ãŒåæ£åXç·åå
æ³ãªã©ãçšããŠèª¿ã¹ãããŸãã(åææ¹æ³ã«ã€ããŠã®è©³çŽ°ã¯ãã€ã³ã°å士ã®å ±åæžã«èšèŒãããŠããŸãïŒã
ãã®ãããªç§åŠçæ€èšŒã®æå³ã¯ãéå
¬éã®ã¯ã¯ãã³æåããã¹ãŠã®äººã«é瀺ãã人ã
ãååãªæ
å ±ãåŸãäžã§ããããã®ã¯ã¯ãã³ãæ¥çš®ãããã©ããã決å®ã§ããããã«ããããšã«ãããŸãã
ããã§æ³šæãã¹ãããšããããŸãããã¡ã€ã¶ãŒã®å
éšåçºè
ã§ããã«ã¬ã³ã»ãã³ã°ã¹ãã³æ°ã¯ãLNPïŒãªãããã»ããã»ããŒãã£ã¯ã«ïŒå°å
¥ããã»ã¹ãèšåãããŠããéšåãç·šéãããã¢ãã«ããšãã¡ã€ã¶ãŒã®FDA EUAç³è«æžé¡ã«ã泚ç®ããŠããŸãããããããFDAãšãã¡ã€ã¶ãŒã¯ããã¡ã€ã¶ãŒãšã¢ããã®mRNAã¯ã¯ãã³ã®éçºã«è³éæäŸããDARPAã«æ¬æãè¡šããŠããã®ãããªç·šéãè¡ã£ãã®ã§ããããKingstonæ°ã¯ãLNPã®äžéšã§ããé
žåã°ã©ãã§ã³ã§ããããšãæããã«ããŸããããããã¯ç·šéã«ãã£ãŠé èœãããŠãããPEGåè質ã«é
žåã°ã©ãã§ã³ãå«ãŸããŠããããšã瀺ããŠããŸãã
Karen Kingston/Pfizer BioNtech EUAã«ãããã¯ã¯ãã³ãžã®LNPæ··å ¥ããã»ã¹ã«é¢ããæ å ±ãåç·šéããã¹ã©ã€ã/ãã¡ãã§çŽ¹ä»ããŠããŸã: ããã°ã©ãã§ã³ãªããµã€ãïŒGOïŒã身äœãšè³ãæ±æããŠãã蚌æ ãCOVIDãšã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãååŠç©è³ªã®çè·¡ãéšæ°Žãççé£å¡©æ°Žããã®ä»ããã¡ã€ã¶ãŒã®å éšåçºè ã§ããã«ã¬ã³ã»ãã³ã°ã¹ãã³ã¯ããã¡ã€ã¶ãŒãšã¢ããã®ã¯ã¯ãã³ã«å«ãŸããPEGåãããè質ããã«GOãå«ãŸããŠããããšã確èªããŸããã
4çš®é¡ã®ã¯ã¯ãã³å šãŠã«é žåã°ã©ãã§ã³ãå«ãŸããŠãã
é žåã°ã©ãã§ã³ïŒGOïŒã¯ã調æ»ãã4ã€ã®ã¯ã¯ãã³ãã¹ãŠããçºèŠãããŸããããã¡ã€ã¶ãŒç€Ÿã®ã¯ã¯ãã³ã«å«ãŸããé žåã°ã©ãã§ã³ã¯ãã©ã»ãã³ã¿ã»ã³ã«ã ã瀟ã®ç§åŠè ãæåã«çºèŠãããã®ã§ããã®çºèŠã¯ã€ã³ã°å士ãåå ããç§åŠè ããŒã ã«ãã£ãŠç¢ºèªãããŸããã以äžã®ç»åã®äžéšã¯ãã€ã³ã°å士ã®è«æã«äœ¿çšãããŠãããã®ã§ãã©ã»ãã³ã¿ã»ã³ã«ã ã瀟ã®å ±åæžããåŸãããç¥èŠã瀺ããŠããŸãã
ãã¡ã€ã¶ãŒç€Ÿè£œã¯ã¯ãã³ã«å«ãŸããã°ã©ãã§ã³ã¯ãå åŠäœçžå·®é¡åŸ®é¡ã§ç¢ºèªããããå³3-Pfizer瀟補ã¯ã¯ãã³ãµã³ãã«ïŒå·ŠïŒãšè¶ é³æ³¢åŠçããéå åé žåã°ã©ãã§ã³ïŒrGOïŒæšæºåïŒå³ïŒïŒSigma-777684ïŒã®éå åé žåã°ã©ãã§ã³ãå«ãæ°Žæ§ç»åç»åãå åŠäœçžå·®é¡åŸ®é¡ã600X /These illustrative images are from the La Quinta Columna Report, June 28, 2021:æ°Žæ§æžæ¿æ¶²äžã®ã°ã©ãã§ã³é žåç©ã®æ€åºïŒãã«ã¬ãã»ãã«ãã£ã³ãã«ã³ãã©ã»ãããªãã
4ã€ã®ã¯ã¯ãã³ãã¹ãŠã«å«ãŸããGOãTEMé¡åŸ®é¡ã§æ±ºå®çã«ç¢ºèªãããïŒå ±åæžã«èšèŒãããŠããéãå³4bã¯ãã°ã©ãã§ã³ç²åã®Xç·åæãã¿ãŒã³ã瀺ããŠããã4çš®é¡ã®CoV - 2 - 19ã¯ã¯ãã³ãã¹ãŠã«TEMé¡åŸ®é¡ã§é žåã°ã©ãã§ã³ã確èªãããïŒæšæºç§åŠæç®ã®ç»åïŒLa Quinta Columnaã®ã¬ããŒãã«ã䜿çšãããŠãã
ãã¡ã€ã¶ãŒç€Ÿè£œã¯ã¯ãã³ã«å«ãŸããTEMé¡åŸ®é¡ã§ç¢ºèªãããæãç³ã¿ã·ãŒãã®ã¡ãã·ã¥ç¶ã®GOïŒå ±åæžã«èšèŒãããŠãããå³5ã¯ããã¡ã€ã¶ãŒç€Ÿè£œã¯ã¯ãã³ã«å«ãŸããã°ã©ãã§ã³ããç²åã®ã¯ã©ã¹ã¿ãŒãåéããŠããããã«ãèŠããã
ãã¡ã€ã¶ãŒã³ãããã£ã¯ã¯ãã³ã®TEMé¡åŸ®é¡ã§ç¢ºèªãããGO/å ±åæžã«èšèŒãããŠããŸããå³6ã¯ããã¡ã€ã¶ãŒç€Ÿã®ãã¯ã¯ãã³ãã«å«ãŸããéå åé žåã°ã©ãã§ã³ã®ç²åãTEMé¡åŸ®é¡ã§èŠ³å¯ãããã®ã§ãããXç·åææ³ã«ããããã®æ§è³ªã¯çµæ¶æ§ã§ããããšãæããã«ãªã£ãŠããã ççŽ ããŒã¹ã®ããç²åã§ããrGO/ãããã®äŸç€ºç»åã¯ã2021幎6æ28æ¥ä»ã®La Quinta Columna Reportã«æ²èŒããããã®ã§ãããæ°Žæ§æžæ¿æ¶²äžã®é žåã°ã©ãã§ã³ã®æ€åºïŒãã«ã¬ãã»ãã«ãã£ã³ãã«ã³ãã©ãããªãŒãã
UVåå æ³ã¯ãUVé¡åŸ®é¡æ³ã§ç¢ºèªãããrGOåžçã¹ãã¯ãã«ã瀺ããŠããŸã/ã¬ããŒãã«èšèŒïŒå³10 - 玫å€åå åæã§ã¯ãéå åé žåã°ã©ãã§ã³ã®ååšã«ããåžçã確èªããã玫å€å¯èŠé¡åŸ®é¡ã§ã®èŠ³å¯ã§ã確èªãããã
çªçŽ ãã±ã€çŽ ããªã³ãå¡©çŽ ãå«ãGOã®Modernaã¯ã¯ãã³ã§çºèŠãããã·ã³ãã©ã¹ãè€åäœ/å ±åæžã«èšèŒãããŠããŸããå³30 ééåé»åé¡åŸ®é¡ã«ããéå åã°ã©ãã§ã³é žåç©ã®100ãã¯ãã³ã®å€§åã·ã³ãã©ã¹ãè€åäœã®çºèŠ
é žåã°ã©ãã§ã³ãçšããè質ãã£ãã·ãããã¡ã€ã¶ãŒã»ãã€ãªã³ããã¯ç€Ÿãšã¢ãã瀟ã®ã¯ã¯ãã³ã§èŠ³æž¬ããã
ãã¡ã€ã¶ãŒãã€ãªããã¯ç€Ÿãšã¢ãã«ã瀟ã®ã¯ã¯ãã³ã§ã¯ãrGOãå«ããªããœãŒã ãã£ãã·ãïŒåå
æ³ã§ç€ºãããïŒãé¡åŸ®é¡ã䜿ã£ãŠç»ååãããã
ããã§æ³šç®ãã¹ãã¯ããã¡ã€ã¶ãŒç€Ÿãšã¢ãã瀟ã®å
¬éè³æãšEUAç³è«è³æã«ã¯ãã«ã¬ã³ã»ãã³ã°ã¹ãã³ãã¢ã³ãã£ã»ã«ãŠããã³å士ãšã®ã€ã³ã¿ãã¥ãŒã§èªã£ã4ã€ã®è質ãããªãLNPã®ã¿ãé瀺ãããŠãããrGOïŒéå
åé
žåã°ã©ãã§ã³ïŒã«ã€ããŠã¯äžå觊ããããŠããªãããšã§ãã
é
žåã°ã©ãã§ã³ã¯ãæ¯æ§è©Šéšã«ãããŠãã现èæ¯æ§ããšãéºäŒåæ¯æ§ãã®äž¡æ¹ãæã€ããšãå€æããŠãããšãã€ã³ã°å士ã¯ææããã
é
žåã°ã©ãã§ã³ãªã©ã®çŽ°èæ¯çŽ ããããšè¡æ ãã§ãã
æ¯çŽ ã«å¯Ÿããè¡æ¶²ã®äž»ãªåå¿ã¯ãèºãžã®é
žçŽ ãå«ãã è¡æ¶²ã®æµãã劚ããè¡æ ã§ãããã®ããããã£ãŒã«ãºã»ãããã§å士ãã¯ãããšããå€ãã®å»åž«ãæè¿è¿°ã¹ãŠããã¯ã¯ãã³æ¥çš®è
ã®è¡æ ã«ã€ããŠãããžã§ãŒã³ã»ã«ããŒå士ããã®ãã¥ãŒã¹ãã¬ã€ã¯130ã§åãäžããŠããŸãããŸããCOVID-19ã«ä»£è¡šãããçªæ¯ãå³ãåŒåžå°é£ãªã©ã®çç¶ããé
žåã°ã©ãã§ã³ã®ååŠç©è³ªã«ããæ±æãšæŸå°ç·ã«ããæ±æã«å¯Ÿããäœã®åå¿ã§ããããšãããã£ãŠããŸãã
ã°ã©ãã§ã³ãçµæ¶åããŠããéã«èµ€è¡çãååºããïŒã°ã©ãã§ã³ãã©ãããæ¥ãã®ããã¯ã¯ãã³ãªã®ããšã¢ããŸã«ãªã®ãã¯ãŸã ããã£ãŠããªãããšNB133ã®Youngå士ã¯èšãïŒã°ã©ãã§ã³ã®ãããªæ¯çŽ ãè¡æ¶²ã«ã©ã®ãããªåœ±é¿ãäžãããã瀺ããŠããã
ââââââââââââââââââââ
ã°ã©ãã§ã³ãã¡ããªãŒã®ããç²åã®æ¯æ§
GFNïŒã°ã©ãã§ã³ãã¡ããªãŒããç²åïŒã¯ãè¡æ¶²-空æ°é¢éãè¡æ¶²-粟巣é¢éãè¡æ¶²-è³é¢éãè¡æ¶²-èç€é¢éãªã©ãééããèºãèèãèŸèãªã©ã«èç©ããããšã§ãçµç¹ã«æ¥æ§ããã³æ ¢æ§ã®å·å®³ãèªçºããããšãã§ãããäŸãã°ãããã€ãã®ã°ã©ãã§ã³ããææã®ãšã¢ããŸã«ã¯ãåžå ¥ãããŠæ°éã«å®è³ªçã«æ²çããæ°ç®¡æ¯æ°éã容æã«è²«éããåŸãäžèºæ°éã«ç§»è¡ããŠããã®åŸã®èèœè «ã®åœ¢æãèºç·ç¶çã被æè ãžã®æ害ãªå¥åº·åœ±é¿ããããã[2, 29]ã...
"ã°ã©ãã§ã³ããææã®æ¯æ§è©äŸ¡ã«ã¯éèå 泚å°ãåºãçšããããŠãããã°ã©ãã§ã³ã¯30åã§ããŠã¹ã®äœå ã埪ç°ããèèãšèè±ã«äœæ¥æ¿åºŠã§èç©ããã[32, 50-52]ã"
ã°ã©ãã§ã³ãã¡ããªãŒããç²åã®æ¯æ§ïŒèµ·æºãšã¡ã«ããºã ã®äžè¬çãªã¬ãã¥ãŒ/ç²åãšç¹ç¶ã®æ¯æ§ã2016幎ãã
ââââââââââââââââââââ
ã€ã³ã°å士ã¯ããã¥ãŒã¹ãã¬ã€ã¯133ã§ãäžã®åçã®ã«ãã·ãã®ç 究ã«ãããŠã100ïŒ é žåã°ã©ãã§ã³ãçºèŠããããšå ±åããŠããŸããè質ã圢æããPEGã¯ã¢ã¬ã«ã®ãŒæ§ãé«ãããšãç¥ãããŠãããã°ã©ãã§ã³ãšåæ§ã«è¡æ¶²ååºãåŒãèµ·ããå¯èœæ§ããããŸãã
ãã¡ã€ã¶ãŒãã€ãªããã¯ç€Ÿã®ã¯ã¯ãã³ã«å«ãŸãããªããœãŒã ã«ãã·ããSEM-Cryoã§çºèŠ/å ±åæžã«èšèŒãããŠãããå³4ã¯ããã¡ã€ã¶ãŒç€Ÿãèªç€Ÿè£œåã«äœ¿çšããŠããrGOãå«ããªããœãŒã ã«ãã·ãã§ããããªããœãŒã ã«ãã·ããç¹å®ã®mRNAååã«ä»çãããŠé žåã°ã©ãã§ã³ãåªä»ãããfGOã®ãªããœãŒã å 容ç©ãç¹å®ã®èåšãè ºãçµç¹ãããªãã¡åµå·£ãšç²Ÿå·£ã骚é«ãå¿èãè³ã«éã蟌ãããã®ãã®ã§ãããç»åã¯SEM-Cryoã®æºåã§åŸããããã®ã§ãã
Moderna瀟ã®ã¯ã¯ãã³ã«å«ãŸããéåãããããã¯ãææ¯ãªã«ãããŠã ã»ã¬ãããå«ãã°ã©ãã§ã³ã§äœãããŠããããšãå€æïŒå ±åæžããå³28ã¯ãModerna瀟㮠"ã¯ã¯ãã³ "ã«å«ãŸããé žåã°ã©ãã§ã³ã®ãããããã瀺ããŠããŸãã
æ¯æ§ã®ããç¡«åã«ãããŠã ã®Modernaã¯ã¯ãã³ã«å«ãŸããæ°æ³¡ç¶ã®ç©ºæŽãšéåããããããGO/Asã§ææãããŠãããå³27ã¯ãModerna瀟㮠"ã¯ã¯ãã³ "ã«å«ãŸããé žåã°ã©ãã§ã³ã®ãããããã瀺ããŠããŸãã
Modernaã¯ã¯ãã³ã«å«ãŸããã·ãªã³ã³ãéãã«ãããŠã ããããªãŠã ããã¿ã³ãé ãã»ã¬ã³ãççŽ ãçªçŽ / å ±åæžã«èšèŒãããŠããŸããå³29ã¯ãModerna瀟㮠"ã¯ã¯ãã³ "ã«å«ãŸããé žåã°ã©ãã§ã³ã®ããç²åã®çŽ°èæ¯æ§ãšéºäŒåæ¯æ§ã®è€åäœã瀺ããŠããŸãã
ãªãã¯ã¹ãã©ãŒã倧åŠã®ã¢ã¹ãã©ãŒãã«ç€Ÿãšã€ã³ã»ã³ç€ŸãŸãã¯ãžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ç€Ÿã®ã¯ã¯ãã³ããã¹ãã³ã¬ã¹éŒãçºèŠãããããšã«ã€ããŠ
ãªãã¯ã¹ãã©ãŒã倧åŠã®ã¢ã¹ãã©ãŒãã«ç€Ÿãšãžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ç€Ÿã®ã¯ã¯ãã³ãããã¹ãã³ã¬ã¹éŒã§ããéãšããã±ã«ããããŠã¯ãã ãå«ãŸããŠããããšãå€æãããå¥åŠãªåœ¢ãããããéå±ã®å¡ã®éåäœãçºèŠãããŸããã
ã€ã³ã°å士ã«ãããšããããã®ã¯ã¯ãã³ãæ¥çš®ãã人ãçªç¶ãäœã«ç£ç³ã®ãããªåŒåã瀺ãã被æ¥çš®è
ã®ç£åããšããçŸè±¡ãããããã®çç±ã«ãããã®ã§ã¯ãªãããšããã
ãã¡ãããé
žåã°ã©ãã§ã³ã«ã¯åžžç£æ§ã®æ§è³ªããããæè¿ã®ãã¥ãŒã¹ã§ã¯ãæ¥æ¬ã®åççã160äžäººåã®ã¢ãã«ããååããçç±ã¯ãã°ã©ãã§ã³ãåŒãèµ·ããç£åã«ãã£ãŠãã€ã¢ã«ãæ±æãããŠããã®ã§ã¯ãªãããšããæžå¿µããã£ããããããããªã(æå³çãªãã®ã§ããããšã¯æããã§ãã)ã
äžã®ç»åã¯ãééåé»åé¡åŸ®é¡ã§ã¹ãã³ã¬ã¹éŒã®ããéå±åéäœã確èªããç¶ããŠãšãã«ã®ãŒåæ£åXç·åå
æ³ãçšããŠXç·ãã€ã¯ããããŒãã§åŸãããã¹ãã¯ãã«ã°ã©ãã瀺ãããã®ã§ãã
ã¢ã¹ãã©ãŒãã«ç€Ÿã®ã¯ã¯ãã³ããçºèŠãããã¹ãã³ã¬ã¹éŒã®è€åæïŒå ±åæžããå³19 - éãã¯ãã ãããã±ã«ã®å·¥åŠçãªéåäœã§ãã¹ãã³ã¬ã¹ã¹ããŒã«ãšããŠç¥ãããã
éãããã±ã«ãã¯ãã ãé
ãã·ãªã³ã³ãç¡«é»ãå¡©çŽ ãã»ã¬ã³ãççŽ ã瀺ãã¢ã¹ãã©ãŒãã«ç€Ÿè£œã¯ã¯ãã³ã®ã¹ãã¯ããã°ã©ã /å ±åæžããå³20ã¯ãã¢ã¹ãã©ãŒãã«ç€Ÿã®ãã¯ã¯ãã³ãã«å«ãŸããå®éåããããã¢åŸ®ç²åãããšãã«ã®ãŒåæ£åã·ã¹ãã ã®Xç·é¡åŸ®é¡ã§æ®åœ±ãããã®ã§ã芳å¯ããããã€ã¯ãããã³ãã埮ç²åã®ååŠçæ§è³ªãæããã«ããŠããŸãã
ãŸããã¢ã¹ãã©ãŒãã«ç€Ÿã®ã¯ã¯ãã³æåã«é¢ããŠã¯ãæ¯æ§ã®ããPEGååç©ã確èªãããããšãé¢é£ããŠããŸãã"XRFïŒèå
Xç·ïŒè£
眮ãçšããŠãã¢ã¹ãã©ãŒãã«ç€Ÿã®ãã¯ã¯ãã³ãã«å«ãŸããã¢ãžã¥ãã³ããè©äŸ¡ãããšããããã¡ã€ã¶ãŒç€Ÿãšã¢ãã瀟ã®ãã¯ã¯ãã³ãã«ãå«ãŸãããã¹ããžã³ãã¹ã¯ããŒã¹ãããªãšãã¬ã³ã°ãªã³ãŒã«ïŒPEGïŒããšãã¬ã³ã¢ã«ã³ãŒã«ã®ä»¥äžã®ååã確èªãããŸããããã®ãã¹ãã®çµæã¯ãå³20ã§èŠãããšãã§ããŸã[9]ã
PEGãšãšãã¬ã³ã¢ã«ã³ãŒã«ã®æ³šå
¥ã¯ãã©ã¡ããçºããæ§ãšéºäŒæ¯æ§ãããããšãç¥ãããŠããŸã[9]ãPEGã¯ãã¢ã¹ãã©ãŒãã«ç€Ÿã®ãã¯ã¯ãã³ãã®æåãèšèŒããããŒã¿ã·ãŒãã«å®£èšãããŠããå¯äžã®ã¢ãžã¥ãã³ãã§ãããããã¡ã€ã¶ãŒç€Ÿãšã¢ãã瀟ã®ãã¯ã¯ãã³ãã«ã¯å«ãŸããŠããŸããã
ãžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ç€Ÿã®ã¯ã¯ãã³ã¯ãéå åé žåã°ã©ãã§ã³ã®ãççŽ ç³»æ¥çå€ãã§å§çž®ãããã¹ãã³ã¬ã¹éŒã®éåäœã瀺ããŠãããã€ã³ã°å士ã«ãããšããã®æ¥çå€ã¯èµ€è¡çã«ãç çãªè¡æ¶²ååºããšãã¹ãã€ã¯ã»ãããã€ã³å¹æããåŒãèµ·ããå¯èœæ§ããããšããã/å ±åæžããå³22 ççŽ ãé žçŽ ãéãããã±ã«ãé žåã°ã©ãã§ã³ã§åºããã¹ãã³ã¬ã¹éŒã®éåäœ
ã¹ãã³ã¬ã¹ïŒéãããã±ã«ãã¯ãã ïŒãšé žåã°ã©ãã§ã³ïŒççŽ ãé žçŽ ïŒã®å«æéã瀺ããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ç€Ÿè£œã¯ã¯ãã³ã®åå åçïŒå ±åæžãããå³23ã¯ãççŽ ãé žçŽ ãéãããã±ã«ã®å çŽ ãé žåã°ã©ãã§ã³ãšäžç·ã«ãªã£ãŠããæ§åã瀺ããŠãã
ãã¡ã€ã¶ãŒç€Ÿããã³ã¢ãã瀟ã®ã¯ã¯ãã³ã«å«ãŸããã¢ã«ãããŠã ããã¹ãã¹ããã®ä»ã®ããã¡ã¿ã«ã¯ãã®ã¶ã®ã¶ããå¡ãå°ã£ãå°çãšããŠæ€åº
ãã¡ã€ã¶ãŒç€Ÿãšã¢ãã瀟ã®ã¯ã¯ãã³ããã¯ãæ§ã
ãªåœ¢ç¶ã®éå©ãªããã¡ã¿ã«ã®ã¹ã©ããžãç ŽçãçºèŠãããŸããããããã¯ãã±ã€é
žã¢ã«ãããŠã ããã¹ãã¹ãã¯ãã ãéããã¿ã³ãã«ãããŠã ãé
ãã»ã¬ã³ãã«ã«ã·ãŠã ãã«ãªãŠã ãã±ã€çŽ ãççŽ ãææ©ç©ã®åéäœã§ããããšãæ§ã
ã«å€æããŠããŸãã
以äžã®ç»åãèŠããšããã¡ã€ã¶ãŒç€Ÿãšã¢ãã瀟ã®ã¯ã¯ãã³ã«ã¯ãå±éºãªåœ¢ãããå¡ããéãã®ã¶ã®ã¶ããç²ç¶ã®ããéå±çãå«ãŸããŠããããšãããããŸãããããã®ããéå±çã¯ãã¹ãŠçŽ°èæ¯æ§ãæã£ãŠããããã¯ãã³åäœã®å€§ãããç°ãªããšã€ã³ã°å士ã¯ææããŠããŸããããããã®ç»åã¯ãXç·ã¹ãã¯ããã¹ã³ããŒã§ååŠæåã確èªããŠããŸãããããã®ç»åã®ãã¹ãŠã®ã¹ãã¯ããã°ã©ããèŠãã«ã¯ãã¬ããŒããã芧ãã ããããã®ç»åã®äžã®åŒçšã¯ãåå
åšããçºèŠãããå
容ã瀺ããŠããŸãã
ãã¡ã€ã¶ãŒç€Ÿã®ã¯ã¯ãã³ã«æ··å ¥ããéå±-GOãããªã®ã¹ããã¥ãŒã«ïŒå ±åæžããå³11ã¯ããã¡ã€ã¶ãŒç€Ÿã®ãããããã¯ã¯ãã³ãã®äžã«ç¢ºèªãããé·ã20umã®éããã¯ãã³ã®ç Žçã§ãççŽ ãé žçŽ ãã¯ãã ãç¡«é»ãã¢ã«ãããŠã ãå¡©åç©ãçªçŽ ãå«ãŸããŠããã
ãã¡ã€ã¶ãŒç€Ÿã®ã¯ã¯ãã³ã«å«ãŸããã¡ã¿ãªãã¯GOãã¬ãŒã¯ã«å«ãŸãããã¹ãã¹ãã¢ã«ãããŠã ãé ïŒå ±åæžãããå³15ã¯ããã¡ã€ã¶ãŒç€Ÿã®ãã¯ã¯ãã³ãã«ç¢ºèªãããããããã³ãã¯ãã³åäœã®åŸ®ç²åã瀺ããŠããŸããé·ã2ãã¯ãã³ã®çœã埮ç²åã¯ããã¹ãã¹ãççŽ ãé žçŽ ãã¢ã«ãããŠã ããããªãŠã ãé ãçªçŽ ã§æ§æãããŠããŸãã
ã¢ãã«ãã¯ã¯ãã³ã«å«ãŸããã¢ã«ãããŠã ãé ãé žåã°ã©ãã§ã³ã®å¡ïŒã¢ã«ãããŠã ãé ãå€ãå«ãŸããŠããïŒïŒã¬ããŒãããå³26 ééåé»åé¡åŸ®é¡ã§èŠããææ©ç©ãšéææ©ç©ãåã蟌ãŸããé žåã°ã©ãã§ã³ã®è€åäœ
ã¢ãã«ãã¯ã¯ãã³ã«å«ãŸããã¢ã«ãããŠã ã·ãªã±ãŒãïŒã°ã©ãã§ã³ãªããµã€ãã®ã·ã£ãŒããªã®ã¶ã®ã¶ã®ã¹ããã¥ãŒã«ïŒå ±åæžãããå³32 ééåé»åé¡åŸ®é¡ã«ããé žåã°ã©ãã§ã³ãšã±ã€é žã¢ã«ãããŠã ã®è€åäœã®èŠ³å¯
ãã¡ã€ã¶ãŒã»ãã€ãªã³ããã¯ç€Ÿè£œã¯ã¯ãã³ã«å«ãŸããå¯çè«ã«ã€ããŠ
ãã¡ã€ã¶ãŒã»ãã€ãªã³ããã¯ç€Ÿã®ã¯ã¯ãã³ã«ãå¯çè«ãæ··å ¥ããŠããããã§ããããã«ãããã¯ã¯ãã³ã«äœãå«ãŸããŠããããšããæããããã©ãã¯ãã€ã³ã°å士ã®å ±åæžã§ç§åŠçã«ææãããŠããããã«ãå šãæ°ããã¬ãã«ã®ãã©ãŒã·ã§ãŒãžãšåŒãäžããããã®ã§ãã
ãå³13ã«èŠããããããª50ãã¯ãã³ã®çŽ°é·ãäœã¯ããã¡ã€ã¶ãŒç€Ÿã®ã¯ã¯ãã³ã®äžã§éãè¬ã®ååšã§ããããã¯è§£ååŠçã«ã¯Trypanosoma cruziãšããå¯çè«ã§ãããã€ãã®å€çš®ã¯èŽæ»æ§ã§ãããåŸå€©æ§å ç«äžå šçå矀ïŒAIDSïŒã®å€ãã®åå ã®äžã€ã§ãããšåå®ãããŠããŸã[人éã®å¯çè«åŠã®ã¢ãã©ã¹ã第4çãããŒã¬ã³ã¹ã»ã¢ãã·ã¥ãšããŒãã¹ã»ãªãªã»ã«ãããŒãž 174 to 178][8]ãã
-ãã¡ã€ã¶ãŒç€Ÿã®ãã¯ã¯ãã³ãã«ã¯å¯çè«ãããã®ãïŒ/èµ°æ»åã»ééåé»åé¡åŸ®é¡ã§CoV-19ã¯ã¯ãã³ã«é žåã°ã©ãã§ã³ãçºèŠ/ãããŒãã»ã€ã³ã°å士/2021幎8æ20æ¥
ããã¯éåžžã«äžå®ãªããšã§ããããã®æããããéã¯ã¯ãã³ããçŽã¡ã«åæ¢ãããããã«ããã¹ãŠã®èªè ããã®ç±ãåŒã³ãããå¿ èŠã§ãããŠã£ãããã£ã¢ã«ãããšããã®çç©ã¯çµç¹ãç Žå£ããè¡ãåžãã"Trypanosoma cruziã¯å¯çæ§ã®ãŠãŒã°ã¬ãã®äžçš®ã§ãããåçåç©ã®äžã§ãããªãããœãŒãã¯ç¹åŸŽçã«ä»ã®çç©ã®çµç¹ãç Žå£ããïŒäž»ã«ïŒè¡æ¶²ããªã³ããåžãããã®ãããªè¡åã¯ãçç©ã«ãã£ãŠç°ãªãç æ°ãåŒãèµ·ãããããç æ°ã®å¯èœæ§ãé«ãããããã人ã§ã¯ã·ã£ãŒã¬ã¹ç ã銬ã§ã¯ããŒãªã³ããµãŒã©ãçã§ã¯ãã«ã»ã©çã«äŒŒãç æ°ããããŸãã"Chagas and Trypanosoma Cruziã«é¢ããCDCã®ãŠã§ããµã€ãã¯ãã¡ããã·ã£ãŒã¬ã¹ç ã«ããããã®å¯çè«ã®äººäœãžã®æãã¹ã圱é¿ïŒå¿äžå šãå€§è žã®ç Žå£ãç®èãè³ãžã®åœ±é¿ãªã©ïŒã«ã€ããŠã¯ãã¡ã€ãšãŒã»ã¯ãªããã¯ããã¡ãã§èª¬æããŠããŸãã
ãã¡ã€ã¶ãŒã»ã¯ã¯ãã³ã»ã¹ãã·ã£ã«è¡ãåžãå¯çè«ïŒå ±åæžããå³13ã¯ããããããã¡ã€ã¶ãŒç€Ÿã®ãã¯ã¯ãã³ãããçºèŠãããé·ãçŽ20ãã¯ãã³ã®ããªãããœãŒãå¯çäœã§ãããççŽ ãé žçŽ ã¯ãã ãç¡«é»ãã¢ã«ãããŠã ãå¡©åç©ãçªçŽ ã§æ§æãããŠããŸãã
ã¬ããŒãããïŒã¯ã«ãŒãºããªãããœãŒãå¯çè«ã®çè¡pHaseã³ã³ãã©ã¹ãé¡åŸ®é¡åç[8]
ã¯ã¯ãã³ã«å«ãŸããmRNAã®éã¯ããããããé žåã°ã©ãã§ã³ã¯è±å¯ã«å«ãŸãã
å ±åæžã«åŸã£ãŠRNAæœåºããã³UVèå
æ€æ»ãè¡ã£ããšãããããããªéã®mRNAããæ€åºããããUVåžåã¹ãã¯ãã«ããã¯ãã¯ã¯ãã³ãã€ã¢ã«ããã®æ°Žæ§ç»åã«å€§éã®é
žåã°ã©ãã§ã³ãå«ãŸããŠããããšã確èªãããäœçžå·®å
åŠé¡åŸ®é¡ã§èŠãããè±å¯ãªã°ã©ãã§ã³ã·ãŒããããæããã§ããã
ãããã®çµæã¯ãLa Quinta Columnaã®ç 究è
ãå ±åãããã®ãšäžèŽããŠããŸããLa Quinta Columna瀟ã®ã¬ããŒãã¯ãã¡ãã§ãã
ãããã¯éèŠãªçºèŠã§ãããã¯ã¯ãã³ã¡ãŒã«ãŒãå
¬è¡šããmRNAã®æ¿å
¥ã¯ãã¯ã¯ãã³ã®å
容ç©ã®ããäžéšã«éãããå±éºã§æ¯æ§ã®ããé
žåçœéã倧éã«å«ãŸããŠããããšã瀺åããŠããŸããçŸåšãäžçäžã®ç§åŠè
ããããã®å
容ç©ãç 究ããŠãããããããŸããããçŸæç¹ã§ã¯ã4瀟ã®ã¯ã¯ãã³ã¡ãŒã«ãŒãããã®åºæ±ãªæ¯æ§ãæã€æåã®ååšãé ããŠããããšã瀺ãååãªèšŒæ ãååšããŠããããã§ããå®éãå ±åæžã®çµè«ã§ã¯ã次ã®ããã«è¿°ã¹ãããŠããŸãã
ãã¯ã¯ãã³ããšããå称ã¯ãå®åçã»æè¡çãªçç±ã§ãç·æ¥ã®æ¿èªãåŸãããã«äœ¿ããããšã¹ã«ã¢ã¿ãŒãžã¥ïŒçç¥ïŒã§ããå¯èœæ§ãé«ã...人é¡ã¯ãé¢ä¿ããããç²åæè¡ã®ããã»ã¹ã«é¢ããŠãäœã®çŽ°èãžã®æªåœ±é¿ãç¹ã«è¡æ¶²ãäœã®çŽ°èã«å¯Ÿããç£æ°æ¯æ§ã现èæ¯æ§ãéºäŒåæ¯æ§ã®ãããã€ãªã€ã³ã¿ã©ã¯ã·ã§ã³å¹æã«ã€ããŠãäœãç¥ããããŠããªããã
"NanoDropTM2000åå å 床èšã®ãã£ãªãã¬ãŒã·ã§ã³ãã§ãã¯åºæã®ãœãããŠã§ã¢ (Thermofisher) "ã«ãããšãå šæ°Žæ§ç»åã®çŽ«å€åžåã¹ãã¯ãã«ã¯747 ng/ulã®æªç¥ã®åžåç©è³ªãšçžé¢ããŠããã
ããããåžè²©ã®ãããïŒThermofisherïŒãçšããŠRNAãæœåºããåŸãRNAç¹ç°çãªQbitèå ãããŒãïŒThermofisherïŒãçšããŠå®éãããšããã6t ug/ulã®ã¿ãRNAã®ååšã«é¢ä¿ããŠããããšãããã£ãããã®ã¹ãã¯ãã«ã¯ã270nmã®rGOã®ããŒã¯ãšäžèŽããã
ä»åçºè¡šãããé¡åŸ®é¡åçã«ãããšããã®åžå 床ã®ã»ãšãã©ã¯ããµã³ãã«å ã®æ¶²äœã«è±å¯ã«å«ãŸããã°ã©ãã§ã³ç¶ã®ã·ãŒãã«ãããã®ã§ãããšèããããŸãã
-ãã¡ã€ã¶ãŒç€Ÿã®ã¯ã¯ãã³ã«ãããmRNAã®å®éåãèµ°æ»åã»ééåé»åé¡åŸ®é¡ã«ããCoV-19ã¯ã¯ãã³ã®é žåã°ã©ãã§ã³ã®çºèŠ/Robert Youngå士/2021幎8æ20æ¥
"340nmã§ã®UVèå ã®æ倧å€ãããµã³ãã«äžã«çžåœéã®rGOãååšããããšã瀺åããŠããïŒBano et al, 2019ïŒ"
-éå åé žåã°ã©ãã§ã³ïŒrGOïŒã«é¢ãããã¡ã€ã¶ãŒç€Ÿã®æ°Žæ§ç»åã®ãŠã«ãã©ãã€ãªã¬ããèå æ€æ»[5]ãèµ°æ»åããã³ééåé»åé¡åŸ®é¡ã¯ãCoVID-19ã¯ã¯ãã³/ Drã®é žåã°ã©ãã§ã³ãæããã«ããŸãã ãããŒãã»ã€ã³ã°ïŒ2021幎8æ20æ¥
å ±åæžããå³9ïŒCytation5ã»ã«ã€ã¡ãŒãžã³ã°ãã«ãã¢ãŒããªãŒããŒåå å 床èšïŒBioteK瀟補ïŒãçšããŠã玫å€åžåã¹ãã¯ãã«ãšèå ã¹ãã¯ãã«ã枬å®ã玫å€åžåã¹ãã¯ãã«ã§ã¯ã270nmã«æ倧ã®ããŒã¯ã確èªãããrGOã®ååšã瀺åããŠããŸãããŸãã340nmã«ãããUVèå ã®æ倧å€ã¯ããµã³ãã«äžã«çžåœéã®rGOãååšããããšã瀺åããŠããïŒBano et al, 2019ïŒã
ã¯ã¯ãã³ã§ã¯ãªãã"éºäŒåæ²»çãšããŠæ©èœãããããã¯ãããžãŒã®è¬ "ã§ã
ãã®4ã€ã®ã¯ã¯ãã³ã調æ»ããç§åŠè
ãã¡ã¯ããããã®ã¯ã¯ãã³ã¯æ²»ççšã¯ã¯ãã³ã§ã¯ãªããåç©çŽ°èããã现èãæµç£ããèå
ã®çŽ°èããåŸãéºäŒåçµã¿æãã¿ã³ãã¯è³ªïŒmRNAïŒã«ãæ¯æ§ã®åŒ·ãé
žåã°ã©ãã§ã³ïŒGOïŒè€åäœãšä»ã®ããç²åãçµåããããã®ã§ãããšçµè«ã¥ããã
ãããã®GOã®éããæ²»éšè¬ãã¯ã麻çºãçºäœãçæ£ãè³åäžãè¡æ ãå¿èçºäœãå¿ççããã«éº»çºã倱æãªã©ãäœçŸäžãã®ã¯ã¯ãã³å·å®³ãåŒãèµ·ãããŠããããšã蚌æãããŠãããã€ã³ã°å士ã¯çŸåããç±³åœCDCã®VAERSãEUã®EudraVigilanceãè±åœã®ã€ãšããŒã«ãŒãã®æ°åïŒããããåããããšãçŸåšçŽ5äžäººãæ»äº¡ããŠããïŒããèšç®ãããšãããããäœçŸäžäººãã®æ»äº¡è
ãåºããŠããããããã®ããŒã¿ããŒã¹ããæ»äº¡ã®èšŒæ ãéãã圌ã®å
æ¬çãªæçš¿ãã芧ãã ãããä»ã®ãã¹ãŠãå¿ããŠãã ããïŒæªæãšæ»ã«é¢ããVAERã®çªå·ãèŠãŠãã ããïŒïŒ2021幎8æ17æ¥
ããã¡ã€ã¶ãŒç€Ÿãã¢ãã瀟ãã¢ã¹ãã©ãŒãã«ç€Ÿãã€ã³ã»ã³ç€Ÿã®å»è¬åã¯ãã¯ã¯ãã³ãã§ã¯ãªããäžè¿°ããããã«ãåç©çŽ°èããã现èãå èããããèå ã®çŽ°èããæœåºããéºäŒåçµã¿æãã®æ žé žã®mRNAã«ãããŸããŸãªããå çŽ ãä»çããè€åé žåã°ã©ãã§ã³ã®ãã埮ç²åã®éåäœã§ããç¹°ãè¿ãã«ãªããŸããããããã®ããããã¯ã¯ãã³ã«å«ãŸããæåã¯ãæ€ç©ãæè«ãé³¥ãåç©ã人éã®çŽ°èèãšãã®éºäŒã«å¯ŸããŠãé«ãç£æ°æ¯æ§ã现èæ¯æ§ãéºäŒæ¯æ§ãæã£ãŠããããã§ã«é節ãªå·å®³ïŒæšå®5å人以äžïŒãæçµçãªæ»ïŒæšå®3,500äžäººä»¥äžïŒã«ã€ãªãã£ãŠããŸã[17][18]ïœ[54]ã"
-ãã£ã¹ã«ãã·ã§ã³ãèµ°æ»åããã³ééåé»åé¡åŸ®é¡ã§CoV-19ã¯ã¯ãã³ã«é žåã°ã©ãã§ã³ãçºèŠ/Robert Youngå士/2021幎8æ20æ¥
COVID-19 "ã¯ã¯ãã³ "ã«ããé žçŽ æ¬ ä¹ãšè¡æ¶²ååºã®çºç
ã€ã³ã°å士ã«ããã°ããããã®èŽåœçãªéã¯ã¯ãã³ã«ãã£ãŠäººäœãè³ãå·å®³ãããã¡ã«ããºã ã¯ãæ¯çŽ ãã¢ã·ããŒã·ã¹ãæŸå°ç·ã®ååšã«ãã£ãŠè¡æ¶²ãååºããèºãžã®é žçŽ ãæ¬ ä¹ããããã«ãã¹ã¯ççšã«ããéåŒåžã§æªåããããšã§èª¬æã§ãããšãããããã«ã€ããŠã¯ãè«æãè¡æ¶²ã®é žçŽ æ¬ ä¹ïŒDICïŒãšèºã®é žçŽ æ¬ ä¹ïŒSARS - CoV 2 & 19ïŒã®åå ã¯äœããã§è©³ããè¿°ã¹ãŠããããã¥ãŒã¹ãã¬ã€ã¯133å·ã®ååã§ã玹ä»ããŠããã
"...ïŒäžç¥ïŒäœåå人ãã®ãããã«ã»ãžã£ããžãããã人ã ãç æ°ã«ãªããçè«çã«ã¯CoV-19ãšããéååšã®ãŠã€ã«ã¹ã«ãããããæ»ã«è³ã£ãŠãã...[54]å¹»ã®ãŠã€ã«ã¹ææã§ã¯ãªããææãåœã®èšŒæ ãçŸå®ã®ããã«èŠããéºäŒåçµã¿æããããmRNAãä»ããŠéå åã°ã©ãã§ã³é žåç©ã®ææ¯ãªé žæåã人äœã®ç¹å®ã®ã¿ãŒã²ããã«å±ããããç çãªè¡æ¶²ååºãé žçŽ æ¬ ä¹ãéåŒåžãäœé žçŽ çããããŠçªæ¯æ»ã«è³ãã®ã§ããã[55][56][57]"
-ãã£ã¹ã«ãã·ã§ã³ãèµ°æ»åããã³ééåé»åé¡åŸ®é¡ã§CoV-19ã¯ã¯ãã³ã«é žåã°ã©ãã§ã³ãçºèŠ/Robert Youngå士/2021幎8æ20æ¥
ãã³ããå¹æããšã¯ãèµ€è¡çãæ¯çŽ ã®æ»æãåãããšãäžã®é¡åŸ®é¡åçã®ããã«ãèµ€è¡çããã¡ãã¡ã«é£ã³åºããéãŸã£ãŠåºãŸã£ãŠããŸãçŸè±¡ã§ãã€ã³ã°å士ã¯é žçŽ æ¬ ä¹çã«é¢ããè«æã®äžã§ããã«è©³ãã説æããŠããŸãã
Newsbreak 133ïœBREAKINGïŒã°ã©ãã§ã³ãã¢ã«ãããŠã ãã¹ãã³ã¬ã¹ãLNP-GOãã£ãã·ããPEGãå¯çè«ã4ã€ã®ã¯ã¯ãã³ããçºèŠãããããã¡ã€ã¶ãŒç€Ÿãã¢ãã瀟ãã¢ã¹ãã©ãŒãã«ç€Ÿããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ç€Ÿ
ã€ã³ã°å士ã¯ã2æéã®è¬æŒã®äžã§ãã¯ã¯ãã³ã«å«ãŸããå±éºãªããç²åãè¡æ¶²ã«ã©ã®ãããªåœ±é¿ãäžãããããŸããç
æ°ãçŸæ£ãææã§ã¯ãªããã¢ãŠããã§ã¯ã·ã§ã³ããäœå
ã§ã©ã®ããã«æ©èœãããã詳ãã説æããŠããŸããã€ã³ã°å士ã¯ãã¯ã¯ãã³ã«å«ãŸããå±éºãªããç²åãã©ã®ããã«è¡æ¶²ã«åœ±é¿ãäžããã®ããç
æ°ãçŸæ£ãææã§ã¯ãªããã¢ãŠããã§ã¯ã·ã§ã³ããå®éã«äœå
ã§ã©ã®ããã«äœçšããã®ãããŠã€ã«ã¹çè«ïŒçŽ°èçè«ïŒã¯ä»ãæã蚌æãããŠããªãçè«ã«éããªãããšãå°åœ¢å»çãçã®å»çã§ããããšãã³ããå¹æã®æ£äœãã¹ãã€ã¯ã¿ã³ãã¯ã®æ£äœãªã©ã詳现ã«èª¬æããŠããŸãããŸãã補è¬äŒç€Ÿã«ã¯äœååãã®å©çããããããå°å¶çãªæ¿åºã«ã¯ãã¡ã·ãºã ãžã®éããããããäžçäžã®äœçŸäžäººãã®çœªã®ãªã人ã
ã«æ»ãšé害ããããããŠãããé©ãã¹ãæ¯æ§ãæã€ãéã¯ã¯ãã³ãã«ã€ããŠã圌ãä»ã®ç§åŠè
ãé¡åŸ®é¡ãåå
æ³ã§çºèŠããããšã説æããŠããŸãã
ãã¥ãŒã¹ãã¬ã€ã¯133ã¯ãäžèšãªã³ã¯ã®BitchuteãBrighteonãOdyseeãRumbleã§ã芧ããã ããŸãã
ââââââââââââââââââââ
ãœãŒã¹
ââââââââââââââââââââ
ðŽå±éºãªã¯ã¯ãã³é¢é£ã®æŽãªããšããã³ã¹ã«ã€ããŠã¯ããã¡ããã芧ãã ããïŒGoogleèªå翻蚳ïŒ
The EveryDay Concerned Citizen
https://translate.google.com/translate?sl=auto&tl=ja&u=https://everydayconcerned.net/2021/08/15/self-assembling-graphene-oxide-nanotech-now-found-also-in-pfizer-vaccine-german-video-reveals-self-assembling-specks-and-crystalline-networks-forming/
ââââââââââââââââââââ
ãäžäººã§ãå€ãã®äººãå©ãããïŒããšãã掻åãç±³è»ãé£åè»ãšå ±ã«æŽ»åããŠãŸããæ¥æ¬ã«éãããäžçååœã§æŽ»åäžã§ãããæ°è»œã«ãåå äžããð
ãã®èšäºãæ°ã«å ¥ã£ãããµããŒããããŠã¿ãŸãããïŒ